Avacopan (Tavneos): The Oral C5a Receptor Blocker Built to Get ANCA Vasculitis Patients Off Steroids (October 2026 Update)
Table of Contents
- Avacopan in one line
- The problem avacopan was built to solve
- How it works: blocking C5a's receptor, not the whole terminal pathway
- The ADVOCATE trial, in numbers
- Why the steroid story matters more than the remission numbers
- Where avacopan sits in the complement map
- Who it is for - and who it is not for
- Safety and monitoring
- The commercial backstory
- The honest bottom line
Avacopan in one line
Avacopan - sold as Tavneos and known in development as CCX168 - is a first-in-class, oral, small-molecule antagonist of the complement C5a receptor (C5aR1, also called CD88). It was discovered and developed by ChemoCentryx (acquired by Amgen in 2022; commercialized outside the U.S. by CSL Vifor) and is taken as 30 mg - three 10 mg capsules - twice daily with food. On October 7, 2021 the FDA approved it as an adjunctive treatment for adults with severe active ANCA-associated vasculitis, the small-vessel autoimmune diseases granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). It is not a stand-alone cure: it is layered on top of rituximab or cyclophosphamide, and its defining purpose is to let patients taper off the high-dose glucocorticoids that have long carried much of the treatment's harm.
The problem avacopan was built to solve
ANCA-associated vasculitis (AAV) is driven by antibodies (ANCAs) that, together with the complement fragment C5a, prime and activate neutrophils. Those over-activated neutrophils attack the walls of small blood vessels, injuring the kidneys, lungs, sinuses, nerves, and skin. For decades, induction therapy has meant rituximab or cyclophosphamide plus months of high-dose glucocorticoids (prednisone). The steroids work, but their cumulative toll - infections, bone loss, diabetes, weight gain, mood and skin changes - is responsible for a large share of the long-term damage patients experience. The unmet need was never just 'more remission'; it was remission with far less steroid exposure. Avacopan was designed to attack that exact gap.
How it works: blocking C5a's receptor, not the whole terminal pathway
When complement is activated, C5 is cleaved into C5a and C5b. C5a is one of the body's most powerful neutrophil-recruiting and -priming signals; it works by binding the C5a receptor (C5aR1/CD88) on neutrophils and other myeloid cells. Avacopan is a selective competitive antagonist of that receptor - it occupies C5aR1 so C5a can no longer switch the neutrophils on. Crucially, it does not block C5b or the downstream membrane-attack complex (MAC). That is a deliberate contrast with anti-C5 antibodies such as eculizumab, which shut down the whole terminal pathway and therefore require meningococcal vaccination and carry a boxed warning for encapsulated-bacterial infection. By narrowing the target to the C5a anaphylatoxin arm, avacopan aims to calm the neutrophil-driven vasculitis while leaving terminal lytic defense comparatively intact.
The ADVOCATE trial, in numbers
Approval rested on the Phase 3 ADVOCATE trial (NCT02994927), published in the New England Journal of Medicine in February 2021. It enrolled 330 adults with newly diagnosed or relapsing severe GPA or MPA across 20 countries, in a double-blind, double-dummy design: everyone received background rituximab or cyclophosphamide, then was randomized to oral avacopan 30 mg twice daily (with a placebo matching the prednisone taper) or to a standard prednisone taper. At week 26, remission rates were essentially the same - 72.3% with avacopan versus 70.1% with prednisone (non-inferior). The separation came later: at week 52, sustained remission was 65.7% with avacopan versus 54.9% with prednisone, a statistically significant superiority (p=0.007). Avacopan patients also had much lower cumulative glucocorticoid exposure and showed improvements in kidney function (eGFR) and quality-of-life scores.
Why the steroid story matters more than the remission numbers
The headline most readers remember is 'avacopan beat prednisone at week 52,' but the more important clinical message is how it got there. ADVOCATE was built so the avacopan arm could avoid a routine high-dose daily prednisone taper, and it showed that this is feasible without losing - in fact while modestly improving - sustained remission. For a disease whose long-term morbidity is substantially iatrogenic (caused by the treatment itself), a regimen that reaches the same or better remission with a fraction of the steroid load is a meaningful shift. It reframes avacopan less as 'another complement drug' and more as a glucocorticoid-sparing tool for autoimmune disease.
Where avacopan sits in the complement map
PepTracker Pro now tracks a growing cluster of complement medicines, and avacopan occupies a node none of the others do. The proximal alternative-pathway drugs act high in the cascade: the factor D inhibitor danicopan and the factor B inhibitor iptacopan sit at the amplification loop, and the C3 inhibitor pegcetacoplan sits at the central convergence point. The terminal C5 drugs - the antibodies crovalimab and pozelimab and the C5 siRNA cemdisiran - block C5 before it is cleaved. Avacopan is different again: it lets C5 be cleaved but blocks only what C5a does at its receptor, sparing C5b and the membrane-attack complex. That makes it the clearest illustration on the site of 'anaphylatoxin-receptor blockade' as a distinct complement strategy.
Who it is for - and who it is not for
Avacopan is indicated for adults with severe active GPA or MPA, given alongside standard immunosuppression. It is adjunctive: it does not replace rituximab or cyclophosphamide, and the label notes it does not eliminate glucocorticoid use in all patients. It is not approved for, or studied as, a treatment for the many other conditions people associate with 'complement' or 'inflammation,' and it has nothing to do with the metabolic, growth, or cosmetic peptides elsewhere on this site. It is a specialist-managed prescription medicine for a specific, serious autoimmune diagnosis.
Safety and monitoring
Avacopan's label carries a Warning for hepatotoxicity: serious liver injury has been seen, so liver enzymes and bilirubin should be checked before and during treatment, and it should not be started in active serious liver disease. It can also cause hypersensitivity reactions, including angioedema, and is contraindicated in patients with serious hypersensitivity to it. Because it blunts part of complement and is given with other immunosuppressants, it can raise infection risk, and live vaccines should be avoided. It is metabolized by CYP3A4, so strong inducers are avoided and the dose is reduced with strong inhibitors. The most common side effects - reported more often than with prednisone - include nausea, headache, hypertension, diarrhea, vomiting, rash, fatigue, upper abdominal pain, dizziness, increased blood creatinine, and paresthesia. Notably, it does not carry the meningococcal boxed warning of the terminal C5 inhibitors.
The commercial backstory
Avacopan came out of ChemoCentryx, a company built around chemokine- and complement-receptor pharmacology. After the 2021 approval, Amgen acquired ChemoCentryx for roughly $4 billion in 2022, folding Tavneos into its inflammation portfolio; outside the United States the drug is marketed by CSL Vifor, with Kissei holding Japanese rights. The molecule has also been explored in other neutrophil- and complement-driven settings, including C3 glomerulopathy and hidradenitis suppurativa, though ANCA-associated vasculitis remains its approved use.
The honest bottom line
Avacopan is a genuinely novel idea executed cleanly: an oral pill that blocks a single complement receptor to quiet the neutrophils that drive ANCA vasculitis, used specifically so patients can take far less steroid. The Phase 3 evidence is solid and the mechanism is distinct from every other complement drug tracked here. But it is a serious prescription medicine for a serious disease, requires liver monitoring, and only works as part of a rituximab- or cyclophosphamide-based regimen under specialist care. Any 'avacopan' or 'Tavneos' offered for sale outside a pharmacy is unverified and should be treated with suspicion.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] FDA label - TAVNEOS (avacopan) capsules, for oral use, prescribing information (2021) Source
- [2] Jayne DRW, Merkel PA, Schall TJ, Bekker P; ADVOCATE Study Group. Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med. 2021;384(7):599-609 Source
- [3] Tavneos (avacopan) FDA Approval History - Drugs.com Source
- [4] FDA Approves Avacopan for the Treatment of ANCA-Associated Vasculitis - The Rheumatologist Source
- [5] Tavneos (avacopan) for the Treatment of ANCA-Associated Vasculitis - Clinical Trials Arena Source
- [6] Amgen to Acquire ChemoCentryx for $4 Billion in Cash (2022) - Amgen Source
Related Articles
Pegcetacoplan: The Cyclic Peptide That Tamed Complement C3 - and Just Became the First Drug for Two Rare Kidney Diseases (July 3, 2026)
Pegcetacoplan started as compstatin, a lab peptide that grabs complement C3. Engineered into a PEGylated cyclic-peptide dimer, it's now approved for PNH, geographic atrophy, and - since July 2025 - as the first treatment for the rare kidney diseases C3G and IC-MPGN. Here's how a peptide reached the market three times over.
Crovalimab (Piasky): The Recycling Anti-C5 Antibody Built for Monthly, At-Home PNH Treatment (October 2026 Update)
Crovalimab (Piasky) is Chugai and Roche's humanized recycling anti-C5 antibody, FDA-approved for paroxysmal nocturnal hemoglobinuria. Its engineering lets one antibody neutralize C5 again and again, so it can be given as a low-volume, once-monthly subcutaneous injection patients give themselves. Here is how it works, what the COMMODORE trials showed, and how it compares with the other C5 drugs.
Iptacopan (Fabhalta): The First Oral Factor B Inhibitor and How It Became a Three-Disease Complement Drug
Novartis's Fabhalta (iptacopan, LNP023) is the first approved oral factor B inhibitor - a pill that clamps the alternative complement pathway at its source. It is now FDA-approved across three rare diseases: PNH, primary IgA nephropathy, and C3 glomerulopathy. In July 2026 it became the first complement inhibitor shown to slow kidney function decline in IgAN, cutting the annual rate of eGFR loss by about 48% versus placebo in APPLAUSE-IgAN.
Danicopan (Voydeya): The First Oral Factor D Inhibitor and the Fix for Extravascular Hemolysis in PNH
AstraZeneca/Alexion's Voydeya (danicopan, ALXN2040) is the first approved oral factor D inhibitor - a pill added on top of a C5 inhibitor to shut down the alternative complement pathway's amplification loop and treat the extravascular hemolysis that eculizumab and ravulizumab leave running in PNH. Here is how factor D inhibition works, what the Phase 3 ALPHA trial showed, and how it compares with iptacopan and pegcetacoplan.